PDCD1 and Marfan syndrome: Lastly, other two MFS patients have been described to receive benefit from immunotherapy-based treatments; a first patient with refractory metastatic MFS, resistant to conventional treatment, was treated with pembrolizumab (i.e., and anti-PD-1), achieving partial response for 18 months (62), while a second patient diagnosed with a high-grade MFS and pulmonary metastases (progressed after surgery, chemoradiotherapy, and an angiogenesis inhibitor treatment) was treated with camrelizumab (i.e., an anti-PD-1), showing metastases shrinkage and stabilization of disease for 18 months.